Express Pathway is powered by patented gene expression technologies that enable efficient processing of disease-specific gene panels of 10-40 genes as a single quantitative reaction in disease areas with unmet clinical need such as oncology, neurodegenerative disease, and other chronic medical conditions. Our goal is to consistently bring novel, high value biomarkers into routine clinical testing through utilization of our proprietary "Discovery & Development Engine".

At the heart of our proprietary process, our Signature Discovery group uses patented and proprietary technologies, such as eXpress Profiling(TM) PCR, and established key partnerships in industry and academia to quickly identify specific multi-gene signatures that can be used routinely and efficiently in the development of translational biomarkers. In concert, our Diagnostics Development group uses the established biomarkers to develop clinically relevant and validated diagnostics under GLP. These disease-specific diagnostic markers are used to differentiate and diagnose disease, and monitor patient populations.

Personalized Medicine is at the heart of Express Pathway Program